Barbara Rita Alevriadou PhD

Barbara Rita Alevriadou

Barbara Rita Alevriadou
PhD

SUNY Empire Innovation Professor in Biomedical Engineering

Department of Biomedical Engineering

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Cardiopulmonary physiology; Cardiovascular Disease; Metabolism; Molecular and Cellular Biology; Molecular Basis of Disease; Research Lab; Signal Transduction; Vascular Medicine

Contact Information
301 Bonner Hall
Department of Biomedical Engineering
University at Buffalo
Buffalo, New York 14260-1900
Phone: (716) 645-8499
alevri@buffalo.edu



Professional Summary:

Dr. Alevriadou received her BS in Chemical Engineering from the Aristotle University, Thessaloniki, Greece, in 1986 and her PhD in Chemical Engineering (Bioengineering & Biosciences Institute) from Rice University, Houston, TX in 1992. Following postdoctoral training in the Department of Molecular & Experimental Medicine at Scripps Research Institute, La Jolla, CA, she joined the BME Department at Johns Hopkins University, Baltimore, MD, as Assistant Professor. In 2003, she joined the BME Center (BME Department, since 2008) and Davis Heart & Lung Research Institute of The Ohio State University as Associate Professor of BME and Internal Medicine, Cardiovascular Medicine. In 2019, she joined the University at Buffalo - The State University of New York as Empire Innovation Professor in BME. Her research on vascular mechanobiology, endothelial mechanotransduction, intracellular signaling, and mitochondrial function is/has been supported by the National Institutes of Health (NIH) and the American Heart Association (AHA). Dr. Alevriadou is a member of the Biomedical Engineering Society (BMES) (1994-present; elected member on the Board of Directors, 2014-2017), Society for Redox Biology & Medicine (SfRBM), North American Vascular Biology Organization (NAVBO), American Physiological Society (APS), and AHA. She regularly reviews for federal/local funding agencies (NIH, NSF, AHA) and biomedical and cardiovascular journals. She serves on the Editorial Board of the American Journal of Physiology-Cell Physiology (2002-present; Associate Editor, 2019-2021), the NAVBO Vascular Biology Publications Alert (2022-present), and Physiological Reports (2023-present).

Education and Training:

  • The Scripps Research Institute, Department of Molecular and Experimental Medicine, La Jolla, CA (1993)
  • Rice University, Houston, TX (1992)
  • Rice University, Houston, TX (1989)
  • Aristotle University, Thessaloniki, Greece (1986)

Employment:

  • Adjunct Professor, Chemical and Biological Engineering, University at Buffalo - The State University of New York, Buffalo, NY (2021-present)
  • SUNY Empire Innovation Professor in Biomedical Engineering, Department of Biomedical Engineering, University at Buffalo - The State University of New York, Buffalo, NY (2019-present)
  • Affiliate Faculty, Davis Heart and Lung Research Institute and the Center for Regenerative Medicine & Cell-Based Therapies, The Ohio State University Wexner Medical Center, Columbus, OH (2003–2019)
  • Associate Professor of Biomedical Engineering, Departments of Biomedical Engineering and Internal Medicine (Cardiovascular Medicine), The Ohio State University, Columbus, OH (2003–2019)
  • Affiliate Faculty in Chemical and Biomolecular Engineering, Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD (1993–2003)
  • Assistant Professor of Biomedical Engineering, Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD (1993–2003)

Awards and Honors:

  • Chair, Mitochondrial Biology Symposium (2021)
  • Empire Innovation Professor and PRODiG Awardee (2019)
  • Associate Editor of the American Journal of Physiology – Cell Physiology (2019)
  • American Physiological Society (APS) STAR Reviewer (2016)
  • Certificate of Recognition for dedication and volunteerism, Society for Redox Biology and Medicine (2016)
  • Board of Directors, Biomedical Engineering Society (2014)
  • Chair, The Ohio State University College of Engineering Committee on the Responsible Conduct of Research (2013)
  • Nominee for the WM Keck Foundation Research Award, The Ohio State University (2011)
  • Co-Chair, Cardiovascular Track, BMES 2009 Annual Meeting (2009)
  • Director's Executive Cabinet, Davis Heart & Lung Research Institute, The Ohio State University (2008)
  • Editorial Board, The American Journal of Physiology - Cell Physiology (2002)
  • Graduate Fellowship, Robert A. Welch Foundation, Rice University (1992)

Research Expertise:

  • MOLECULAR BASIS OF CARDIOVASCULAR DISEASE: Understanding the role of hemodynamics and chemical agonists in regulating the endothelial phenotype and initiating atherosclerosis/coronary artery disease and other cardiovascular diseases/conditions (cardiac ischemia/reperfusion injury, heart failure, diabetes, etc.)
  • VASCULAR ENDOTHELIAL (DYS)FUNCTION: Assessing the cell's calcium and reactive oxygen species (including nitric oxide) signaling, mitochondrial function and metabolism, gene expression/protein synthesis, inflammation, and propensity for apoptosis
  • VASCULAR MECHANOBIOLOGY / MECHANOTRANSDUCTION: Effects of hemodynamic forces (e.g., shear stress, pressure) and/or oxygen tension on the vascular endothelium; Signal transduction due to changes in the cell‘s mechanochemical environment

Research Centers:

  • Center for Research in Cardiovascular Medicine

UB 2020 Strategic Strengths:

  • Health and Wellness Across the Lifespan
  • Molecular Recognition in Biological Systems and Bioinformatics

Grants and Sponsored Research:

  • August 2018–June 2022
    Control of Endothelial Mechanotransduction by the Mitochondrial Ca2+ Uniporter: Implications for Atherosclerosis. Alevriadou BR (PI), Madesh M (co-PI). Agency: NIH/NHLBI. Type: R01 HL142673. Total cost: $1.82 million
    Role: Principal Investigator
  • January 2016–June 2018
    Redox Regulation of Autophagy in Postischemic Vascular Endothelial Cells. Alevriadou BR (PI), Zweier JL (co-I). Agency: AHA. Type: Grant-In-Aid. Total cost: $154,000
    Role: Principal Investigator
  • June 2011–May 2013
    Emerging Functions of Mitochondrial Fission in Postischemic Endothelial Cells. Alevriadou BR (PI), Matzavinos A (co-I). Agency: NIH/NHLBI. Type: R21 HL106392. Total cost: $423,000
    Role: Principal Investigator
  • January 2008–December 2009
    Mechanoregulation of Endothelial Mitochondrial Function. Alevriadou BR (PI), Chen Y-R (co-I), Szeto HH (co-I). Agency: NIH/NHLBI. Type: R21 HL091417. Total cost: $410,000
    Role: Principal Investigator
  • December 2001–February 2006
    Reperfusion-Induced Endothelial Cell Dysfunction. Alevriadou BR (PI), Irani K (co-I). Agency: NIH/NHLBI. Type: R01 HL067027. Total cost: $1.25 million
    Role: Principal Investigator

Journal Articles:

See all (22 more)

Professional Memberships:

  • American Physiological Society (APS) (Member, Cell and Molecular Physiology Section); Member (2020–present)
  • American Heart Association (AHA) (Member, Council on Basic Cardiovascular Sciences) (2010–present)
  • Society for Redox Biology and Medicine (SFRBM) (Women in Science Mentoring Committee, 2005-present) (1995–present)
  • North American Vascular Biology Organization (NAVBO) (Founding Member) (1994–present)
  • Biomedical Engineering Society (BMES) (Board of Directors 2014-17; Student Affairs and Diversity Committees 2014-18; International Affairs Committee 2018-present) (1994–present)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

301 Bonner Hall
Department of Biomedical Engineering
University at Buffalo
Buffalo, New York 14260-1900
Phone: (716) 645-8499
alevri@buffalo.edu